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Abstract
Objective: Drug use and receipt of highly active antiretroviral therapy (HAART) were assessed in HIV-infected persons from
the Comprehensive Care Center (CCC; Nashville, TN) and Johns Hopkins University HIV Clinic (JHU; Baltimore, MD) between
1999 and 2005.
Methods: Participants with and without injection drug use (IDU) history in the CCC and JHU cohorts were evaluated.
Additional analysis of persons with history of IDU, non-injection drug use (NIDU), and no drug use from CCC were
performed. Activity of IDU and NIDU also was assessed for the CCC cohort. HAART use and time on HAART were analyzed
according to drug use category and site of care.
Results: 1745 persons were included from CCC: 268 (15%) with IDU history and 796 (46%) with NIDU history. 1977 persons
were included from JHU: 731 (35%) with IDU history. Overall, the cohorts differed in IDU risk factor rates, age, race, sex, and
time in follow-up. In multivariate analyses, IDU was associated with decreased HAART receipt overall (OR=0.61, 95% CI:
[0.45–0.84] and OR=0.58, 95% CI: [0.46–0.73], respectively for CCC and JHU) and less time on HAART at JHU (0.70, [0.55–
0.88]), but not statistically associated with time on HAART at CCC (0.78, [0.56–1.09]). NIDU was independently associated
with decreased HAART receipt (0.62, [0.47–0.81]) and less time on HAART (0.66, [0.52–0.85]) at CCC. These associations were
not altered significantly whether patients at CCC were categorized according to historical drug use or drug use during the
study period.
Conclusions: Persons with IDU history from both clinic populations were less likely to receive HAART and tended to have
less cumulative time on HAART. Effects of NIDU were similar to IDU at CCC. NIDU without IDU is an important contributor to
HAART utilization.
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Introduction
The dual global pandemics of substance abuse and HIV
threaten not only individual but also public health. Injection drug
use (IDU) was the HIV transmission risk factor for 35% of females
and 20% of males with AIDS reported through 2007 in the United
States (US) [1]. The role of IDU in HIV transmission varies
according to geographic region. The distribution of AIDS cases
due to IDU in 2006 was approximately 25% and 50% greater for
females and males, respectively, in the Northeastern US compared
with those in Southern and Midwestern states [2]. Beyond the US,
IDU is fueling HIV transmission in Eastern Europe and Central,
South, and South-East Asia, and is estimated to account for
approximately one-third of new HIV infections outside Sub-
Saharan Africa [3]. Injection drug users often receive their HIV
diagnosis late and may have worse clinical outcomes compared to
persons without IDU [4].
The use of highly active antiretroviral therapy (HAART) has led
to sustained decreases in HIV-related morbidity and mortality
[5,6]. Successful long-term outcomes require a high degree of
patient adherence and persistence with therapy [7,8,9]. Substance
use may be associated with decreased adherence to HAART [10–
12] and subsequent increased rates of virologic failure and HIV
disease progression [13,14]. However, the association of drug use
with reduced adherence is not uniform, as participants in the
Smartest Women’s project reported relatively high levels of
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[15]. Patient persistence with HAART, reflecting the duration of
time on therapy, was decreased among former and current
injection drug users in Baltimore, with 78% of individuals having
one or more treatment interruptions; persons reporting daily IDU
had a higher probability of treatment interruptions [16]. Whether
non-injection drug use (NIDU) exerts a similar influence on
patient persistence with HAART is not known [9].
Behaviors related to drug use and illicit drugs themselves may
lead to poorer treatment outcomes and high risk of HIV
transmission. Potential effects of drug use include neurocognitive
impairment, psychosocial dysfunction, or exacerbation of psychi-
atric illness. Altered judgment and decision-making may lead to
high-risk sexual behavior and attendant risk of acquiring other
sexually-transmitted infections, which in turn may facilitate HIV
transmission [17] and disease progression [18]. Exchange of sex
for drugs or money may occur in users of any illicit substance,
especially crack cocaine [19–21]. Persons with substance use
disorders may transition through correctional facilities, which may
be associated with cyclic interruptions in HIV treatment [9,16].
There also are possible mechanisms by which cocaine and opiates
could directly affect HIV disease outcomes. Studies in vitro, and in
animals and humans have suggested that cocaine and opiates have
direct effects on HIV replication and T cell immunology [22–27].
A history of IDU has been associated with delayed initiation of
HAART [28–31]. Despite this, an increased risk of HIV disease
progression and death has not been uniformly reported in studies
of IDU in the HAART era [31–33]. These outcomes may vary
due to differences in study design and the populations evaluated.
NIDU also is common in patients with HIV infection; an
estimated prevalence of 40–60% has been reported [34,35].
Crack cocaine users have been shown to have worse HIV
outcomes compared with non-users [36], and this effect was
independent of HAART use in one cohort [37]. NIDU is difficult
to characterize, however, as it often includes overlapping use of
many substances, each with differing effects on the user. Patterns
of NIDU over time may be heterogeneous, erratic, and dynamic,
making accurate measurement of use over time complicated [38].
Few studies have examined the association of NIDU with HAART
utilization and persistence. We conducted a retrospective study of
two geographically distinct urban US cohorts to identify
relationships between IDU, receipt of HAART, and demographic
features of the cohorts. We also performed targeted analyses in a
single cohort in the Southeastern US to characterize relationships
between NIDU and HAART utilization in this setting.
Methods
Ethics Statement
The study was approved by the Vanderbilt University and
Johns Hopkins Institutional Review Boards. Exemption from
informed consent was approved by the Vanderbilt University
Institutional Review Board. Written informed consent was
obtained for all participants from Johns Hopkins. To maintain
patient confidentiality, non-identifiable patient data were used in
the analyses.
Study Population and Database
The overall cohort included persons who had their first
outpatient visit at the Vanderbilt-affiliated Comprehensive Care
Center (CCC) in Nashville or the Moore Clinic for HIV Care at
Johns Hopkins University (JHU) in Baltimore between January 1,
1999 and December 31, 2004. Subjects must have had at least two
outpatient visits during the study period. Study follow-up for each
patient was censored at the date of death, date of last clinic
encounter if the patient met lost-to-follow-up criteria (defined as
$18 months between clinic encounters without laboratory data
during the intervening time), or December 31, 2005 if the last
clinic encounter or death date was after that date.
The CCC is the largest HIV outpatient care center in
Tennessee and includes three satellite clinics in rural Middle
Tennessee. In addition to providing specialized HIV medical care,
the CCC provides case management and coordination of mental
health services including substance abuse treatment programs.
Clinical data have been entered directly into an electronic medical
record (EMR) since 1997, either by medical providers at the time
of the patient encounter, by automated laboratory data upload, or
by retrospective entry by clinic personnel (for updating data such
as death, hospitalization, interim diagnoses, and laboratory results
received from outside sources). Risk factors for HIV acquisition,
including history of IDU, are identified by clinicians at patient
enrollment at CCC. Medical charts were reviewed by trained
abstractors to ascertain additional history of IDU, NIDU and
heavy use or abuse of alcohol (defined below).
JHU provides integrated primary and subspecialty care for a
large proportion of HIV-infected patients in the Baltimore
metropolitan area. An observational, longitudinal, clinical cohort
of adult patients receiving HIV care at JHU has been maintained
since 1990 [39]. Enrollment into the cohort corresponds to
enrollment at JHU. Comprehensive demographic, clinical,
therapeutic, and laboratory data are collected at baseline
(enrollment) and updated at 6-month intervals using structured
data collection forms and coding criteria. These data are updated
from clinic visits and inpatient admissions records, laboratory
testing, pharmacy, social services, and all other available clinical
sources via standardized abstraction. Nonexclusive risk factors for
HIV acquisition (including IDU) are identified by clinicians when
patients enroll in the cohort.
Exposure and Outcome Definitions
Persons from the CCC cohort were categorized into three
mutually exclusive groups for analysis: persons with an IDU
history, persons with NIDU history, and persons with neither IDU
nor NIDU history. The overall cohort (including JHU) was
categorized into two groups for analysis: persons with an IDU
history and those with no history of IDU. For the CCC cohort,
persons were considered to have a history of IDU if there was any
record of IDU as self-reported probable route of HIV infection, or
any corresponding ICD-9 diagnoses or free text entered into the
EMR by providers. For the JHU cohort, IDU as either provider-
entered diagnosis or self-reported HIV risk is captured as part of
structured data abstraction procedures [40].
NIDU at CCC was defined as any record of substance abuse/
use, dependence, or addiction, or self-reported heavy alcohol use,
or recreational drug use, of any kind or amount, excluding anyone
whose HIV risk factor was IDU. After an electronic query of ICD-
9 diagnosis codes for abuse and/or dependence identified persons
with IDU as HIV risk factor and those with a history of NIDU,
chart validation was performed on the remaining persons to assess
substance use through notation by the provider of concern about
drug or alcohol use, notation of a patient entering a drug or
alcohol rehabilitation program, notation of non-injection prescrip-
tion drug abuse, or indication of medical, legal, or social problems
resulting from drug or alcohol use. Drugs used in the diagnosis of
NIDU included cocaine, crack cocaine, methamphetamine,
heroin, opiates, marijuana, and ‘‘party drugs’’ such as methyle-
nedioxymethamphetamine and nitrous oxide. Alcohol use was
categorized as NIDU if there was a provider notation in the chart
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alcoholic liver disease). To account for potential weakness in the
pertinence of a history of drug use to the receipt of HAART,
additional reviews of charts of persons categorized as having
historical IDU and NIDU were conducted at CCC to assess for
active drug use during the study period.
Baseline (enrollment) demographics and laboratory values were
obtained from the medical record. Baseline CD4
+ T cell count and
plasma HIV-1 RNA level were defined as the first values obtained
#60 days prior to or any time after the first clinic visit between
January 1, 1999 and December 31, 2004.
The primary outcomes of interest were ever receiving HAART
and cumulative time on HAART during the study period. HAART
was defined as (1) at least 2 nucleoside reverse-transcriptase
inhibitors (NRTIs) in combination with at least 1 protease inhibitor
(PI)and/ornon-NRTI(NNRTI); (2)one NRTI and anyPI and any
NNRTI; or (3) at least 3 NRTIs. Persons who received HAART for
$ 7 days were classified as having ever received HAART. Time on
HAART included cumulative HAART between January 1, 1999
and December 31, 2005, including HAART that began prior to
January 1, 1999. HAART start was set at January 1, 1999 if
HAART start occurred prior to that date and HAART end date
was set as December 31, 2005 if HAART stop occurred after that
date. Proportional time on HAART was calculated as cumulative
weeks on HAART for each individual who ever received HAART
divided by the follow-up time in weeks for that individual. For
analyses,this outcome was dichotomizedas$ or,95% ofavailable
follow-up time on HAART [41].
Statistical analysis
Categorical variables were compared with the x
2 or Fisher’s
exact tests. Continuous variables are shown as medians and were
compared with the Wilcoxon rank-sum (Mann-Whitney U)o r
Kruskal-Wallis tests. Logistic regression models were constructed
to analyze receipt of HAART and proportional time on HAART
according to drug use category and site of care. Other covariates
adjusted for in multivariate analyses included baseline demo-
graphics, cumulative follow-up time, CD4
+ T cell count
categorized as , or $200 cells/mm
3, and HIV-1 RNA level
categorized as # or .5 log10 (100,000) copies/mL. Separate
multivariate logistic regression models were constructed a priori for
the CCC and JHU cohort databases. These included identical
models without NIDU history (Model 1). A corresponding model
to assess the effect of NIDU in the CCC cohort included the same
demographic and laboratory variables as the other models as well
as IDU and NIDU history (Model 2). Secondary models including
active drug use during the study period, instead of historical drug
use, were used to assess the association of activity of drug use with
receipt of HAART and proportional time on HAART in the CCC
cohort. All analyses were performed using Stata SE (version 10.0;
Stata Corporation, College Station, TX).
Results
CCC cohort analysis, total and according to IDU risk and
drug use categories (Table 1)
The total CCC study cohort was predominantly white and male
and median age was 37 years. Of the 1745 persons included, 796
(46%) persons met criteria for history of NIDU, 268 (15%) persons
met criteria for history of IDU, and 681 (39%) persons had no
drug use history. Comparisons between the three drug use
categories demonstrated statistically significant differences in age,
race, sex, and follow-up time during the study period. There were
differences in likelihood of ever receiving HAART, with persons
Table 1. Clinical and demographic characteristics of Comprehensive Care Center study cohort, total and according to IDU risk and
drug use categories.
a
Characteristic
Total cohort
(n=1745) No IDU history
IDU history
(n=268) P valuec
Total
(n=1477)
No drug use
history (n=681)
NIDU history
b
(n=796)
Age in years 37 (31–43) 37 (30–43) 36 (29–43) 37 (32–42) 41 (35–45) ,0.001
Black race 660 (38) 536 (37) 225 (33) 311 (39) 124 (46) ,0.001
Female sex 419 (24) 356 (24) 190 (28) 166 (21) 63 (24) 0.007
Follow-up time in weeks 119 (66–207) 124 (68–211) 122 (61–203) 125 (73–223) 100 (45–173) ,0.001
Baseline CD4
+ T cell count
d, cells/mm
3 306 (136–504) 308 (136–500) 306 (120–483) 308 (151–513) 288 (140–506) 0.56
Baseline HIV-1 RNA
d,l o g 10 copies/mL 4.4 (3.2–5.0) 4.4 (3.3–5.1) 4.4 (3.1–5.1) 4.4 (3.4–5.1) 4.4 (3.0–4.9) 0.44
Baseline CD4
+ T cell count
d ,200 cells/mm
3 582 (34) 492 (34) 227 (34) 265 (33) 90 (34) 0.99
Baseline HIV-1 RNA
d ,400 copies/mL 299 (17) 247 (17) 136 (20) 111 (14) 52 (20) 0.004
HAART ever during study period
e 1282 (73) 1109 (75) 536 (79) 573 (72) 173 (65) ,0.001
Time on HAART in weeks
f 100 (46–175) 102 (48–177) 103 (46–175) 102 (53–179) 88 (30–162) 0.06
% follow-up time on HAART among ever
exposed to HAART (n=1282)
90 (58–99) 91 (58–99) 94 (61–99.8) 88 (54–98.7) 88 (61–99.5) 0.02
aData are median (interquartile range) or n (%).
bNon-injection drug use history defined as any record of substance abuse/dependence/addiction or self-reported use of heavy alcohol or past or current recreational
drug use, of any kind or amount, excluding anyone whose HIV risk is injection drug use.
cP values are for comparisons between the three drug use categories using Kruskal-Wallis or Chi-squared tests.
dCD4
+ T cell counts and plasma HIV-1 RNA levels not available for all persons; data shown are for those persons with data available. Baseline laboratory values defined as
the first value obtained on or after the initial office visit, between January 1, 1999 and December 31, 2004.
eDefined as at least 7 days of continuous HAART.
fAmong persons ever exposed to HAART.
IDU = injection drug use; CCC = Comprehensive Care Center, Nashville, TN; HAART = highly active antiretroviral therapy.
doi:10.1371/journal.pone.0018462.t001
Drug Use and HAART
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18462with no drug use history having the greatest likelihood and persons
with a history of IDU having the lowest. The proportion of follow-
up time on HAART was also greatest among those with no drug
use compared with those having a history of either NIDU or IDU.
There was no significant difference in median CD4
+ T cell count
or plasma HIV-1 RNA level at baseline between the substance use
categories. The median year of cohort entry was 2002. Earlier year
of cohort entry at CCC was associated with greater likelihood of
ever receiving HAART, but lower likelihood of having $95% of
follow-up time on HAART (P,0.01 for both).
There were 76 participants with active IDU and 776 with active
NIDU recorded during the study period. Active NIDU was
present for 644 persons (81%) who were categorized as history of
NIDU and for 132 persons (49%) categorized as history of IDU.
Among individuals with history of IDU, 69 (26%) had active IDU
during the study period.
JHU cohort analysis, total and according to IDU status
(Table 2)
The total JHU study cohort was predominantly black and male
and median age was 39 years. Of the 1977 persons included, 731
(37%) persons met criteria for history of IDU. Comparisons
between IDU and non-IDU categories demonstrated that
individuals with a history of IDU were significantly older, more
likely to be black, and less likely to ever receive HAART, and had
less follow-up time on HAART during the study period. There
was no significant difference in sex, follow-up time during the
study period and median CD4
+ T cell count and HIV-1 RNA
level at baseline between the drug use categories. The median year
of cohort entry was 2001. Earlier year of cohort entry at JHU was
associated with greater likelihood of ever receiving HAART
(P=0.04) but not associated with having $95% of follow-up time
on HAART (P=0.5).
Multivariate models of predictors of ever receiving
HAART and receiving HAART $95% of follow-up time in
the CCC cohort (Table 3)
Two logistic regression models were used to assess the effects of
age, baseline laboratory values, sex, race, follow-up time, and drug
use history on the receipt of HAART in the CCC study cohort.
Model 1included only IDU history to be consistent with results of
the corresponding model of JHU data (shown in Table 4). Model 2
included both IDU and NIDU history. CCC participants with
baseline CD4
+ T cell count ,200 cells/mm
3 and HIV-1 RNA
level .5 log10 copies/mL and longer follow-up time on study were
significantly more likely to receive HAART, whereas black race,
IDU history and NIDU history each were associated with a lower
likelihood of HAART receipt. Among persons exposed to
HAART, baseline HIV-1 RNA level .5 log10 copies/mL, black
race, and NIDU history were inversely associated with receipt of
HAART $95% of follow-up time. In Model 2 adjusted for both
NIDU and IDU, history of IDU was significantly associated with a
decreased likelihood of receipt of HAART $95% of follow-up
time. Although female sex had a positive association with HAART
use ever, women were significantly less likely to receive HAART
$95% of follow-up time in the CCC cohort.
Multivariate models of predictors of ever receiving
HAART and receiving HAART $95% of follow-up time in
the JHU cohort (Table 4)
Receipt of HAART in the JHU study cohort was assessed using
logistic regression models that included the effects of age, baseline
laboratory values, sex, race, follow-up time, and IDU history. JHU
participants with baseline CD4
+ T cell count ,200 cells/mm
3 and
HIV-1 RNA level .5 log10 copies/mL and longer follow-up time
on study were significantly more likely to receive HAART, whereas
female sex, black race, and IDU history each were associated with a
Table 2. Clinical and demographic characteristics of the Johns Hopkins University study cohort, total and according to IDU risk
category.
a
Characteristic
Total cohort
(n=1977)
No IDU history
(n=1246)
IDU history
(n=731) P value
b
Age in years 39 (34–45) 38 (32–44) 41 (37–46) ,0.001
Black race 1458 (74) 859 (69) 599 (82) ,0.001
Female sex 683 (35) 438 (35) 245 (34) 0.46
Follow-up time in weeks 171 (93–255) 176 (97–257) 164 (88–162) 0.25
Baseline CD4
+ T cell count
c, cells/mm
3 273 (105–466) 274 (98–467) 272 (117–461) 0.79
Baseline HIV-1 RNA
c,l o g 10 copies/mL 4.4 (3.1–5.1) 4.4 (3.1–5.1) 4.4 (3.2–5.1) 0.56
Baseline CD4
+ T cell count
c ,200 cells/mm
3 764 (39) 486 (39) 278 (38) 0.70
Baseline HIV-1 RNA
c ,400 copies/mL 352 (18) 230 (19) 122 (17) 0.60
HAART ever during study period
d 1429 (72) 948 (76) 481 (66) ,0.001
Time on HAART in weeks
e 123 (52–220) 129 (57–226) 112 (41–209) ,0.001
% follow-up time on HAART among ever exposed to
HAART (n=1429)
96 (55–100) 97 (63–100) 87 (40–100) ,0.001
aData are median (interquartile range) or n (%).
bP-values are for comparisons between IDU and no IDU history groups using Wilcoxon rank-sum or Fisher’s exact tests.
cCD4
+ T cell counts and plasma HIV-1 RNA levels not available for all persons; data shown are for those persons with data available. Baseline laboratory values defined as
the first value obtained on or after the initial office visit, between January 1, 1999 and December 31, 2004.
dDefined as at least 7 days of continuous HAART.
eAmong persons ever exposed to HAART.
IDU = injection drug use; HAART = highly active antiretroviral therapy.
doi:10.1371/journal.pone.0018462.t002
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HAART, baseline CD4
+ T cell count ,200 cells/mm
3 and longer
follow-up time on study were associated with receipt of HAART
$95% of total follow-up time. Baseline HIV-1 RNA level .5 log10
copies/mL, black race, and IDU history were inversely associated
with receipt of HAART $95% of total follow-up time.
CCC cohort analysis using multivariate models of
predictors of receiving HAART, accounting for active
drug use during the study period
Models including active drug use during the study period, instead
of historical drug use,were used to assess the association of activity of
drug use with receipt of HAARTand proportional time on HAART
in the CCC cohort. These analyses showed patterns of associations
between active drug use and receipt of HAART that were similar to
those observed using historical drug use. In models adjusted for both
active NIDU and IDU, IDU during the study period was associated
with decreased likelihood of receipt of HAART ever (OR=0.51,
95% CI: 0.29 to 0.89) and $95%oftotal follow-up time(OR=0.46,
95% CI: 0.24 to 0.87), as was NIDU (OR=0.60, 95% CI: 0.47 to
0.77 and OR=0.72, 95% CI: 0.57 to 0.91, respectively for HAART
ever and $95% of total follow-up time).
Discussion
This study was based on data compiled from the CCC, which
serves urban and rural Tennessee, and the urban JHU cohort in
Table 3. Multivariate logistic regression models of predictors of (A) ever receiving HAART and (B) receiving HAART $95% of
follow-up time in the Comprehensive Care Center study cohort.
A. Predictors of ever receiving HAART (N=1730)
B. Predictors of receiving HAART $95% of follow-up
time
a (N=1275)
Covariate Model 1
b Model 2
b Model 1
b Model 2
b
OR 95% CI P OR 95% CI P OR 95% CI P OR 95% CI P
Age (per year) 1.03 1.02–1.04 ,0.001 1.03 1.02–1.04 ,0.001 1.02 1.01–1.04 ,0.001 1.02 1.01–1.04 0.001
Baseline CD4
+ T cell count
b
,200 cells/mm
3
4.40 3.17–6.12 ,0.001 4.43 3.19–6.16 ,0.001 1.13 0.88–1.46 0.33 1.15 0.89–1.48 0.29
Baseline HIV-1 RNA
c .5l o g 10
copies/mL
1.67 1.12–2.34 0.003 1.68 1.20–2.35 0.003 0.63 0.48–0.82 0.001 0.62 0.47–0.81 0.001
Female sex 1.27 0.96 1.69 0.10 1.22 0.92–1.63 0.17 0.75 0.57–0.99 0.05 0.71 0.53–0.94 0.02
Black race 0.56 0.43–0.71 ,0.001 0.57 0.44–0.73 ,0.001 0.64 0.50–0.81 ,0.001 0.65 0.51–0.83 0.001
Follow-up time (per year) 1.66 1.53–1.81 ,0.001 1.68 1.54–1.83 ,0.001 0.96 0.90–1.02 0.21 0.97 0.91–1.03 0.28
IDU history 0.61 0.45–0.84 0.003 0.47 0.33–0.67 ,0.001 0.78 0.56–1.09 0.15 0.63 0.44–0.90 0.01
NIDU history
b - - - 0.62 0.47–0.81 0.001 - - - 0.66 0.52–0.85 0.001
aAmong those ever exposed to HAART.
bModel 1 did not include NIDU history, in order to be consistent with results of the corresponding model of JHU data. Model 2 included both IDU and NIDU, as well as
the other covariates shown. IDU and NIDU were mutually exclusive definitions (see METHODS), thus Model 2 results do not denote independent relationships between
drug-use categories and outcome variables.
cCD4
+ T cell counts and plasma HIV-1 RNA levels not available for all persons; data shown are for those persons with data available. Baseline laboratory values are
defined as the first values obtained on or after the initial office visit, between January 1, 1999 and December 31, 2004.
HAART = highly active antiretroviral therapy; OR = odds ratio; CI = confidence interval; IDU = injection drug use; NIDU = non-injection drug use.
doi:10.1371/journal.pone.0018462.t003
Table 4. Multivariate logistic regression models of predictors of (A) ever receiving HAART and (B) receiving HAART $95% of
follow-up time in the Johns Hopkins University study cohort.
Covariate
Predictors of ever receiving
HAART (N=1960)
Predictors of receiving HAART $95% of
follow-up time
a (N=1422)
OR 95% CI P OR 95% CI P
Age (per year) 1.01 0.999–1.02 0.08 1.02 1.00–1.03 0.02
Baseline CD4
+ T cell count
b ,200 cells/mm
3 5.16 3.90–6.82 ,0.001 1.82 1.45–2.29 ,0.001
Baseline HIV-1 RNA
b .5l o g10 copies/mL 1.93 1.44–2.59 ,0.001 0.76 0.60–0.98 0.03
Female sex 0.71 0.56–0.89 0.003 0.84 0.67–1.06 0.15
Black race 0.70 0.54–0.91 0.007 0.62 0.48–0.79 ,0.001
Follow-up time (per year) 1.32 1.24–1.40 ,0.001 1.12 1.06–1.19 ,0.001
IDU history 0.58 0.46–0.73 ,0.001 0.70 0.55–0.88 0.002
aAmong those ever exposed to HAART.
bCD4
+ T cell counts and plasma HIV-1 RNA levels not available for all persons; data shown are for those persons with data available. Baseline laboratory values are
defined as the first values obtained on or after the initial office visit, between January 1, 1999 and December 31, 2004.
HAART = highly active antiretroviral therapy; OR = odds ratio; CI = confidence interval; IDU = injection drug use.
doi:10.1371/journal.pone.0018462.t004
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HAART utilization in two different HIV outpatient populations
with up to five years of follow-up. The large sample size provides
an opportunity to add to the current literature that reports
inconsistent effects of IDU on various HIV outcomes, including
HAART use [35]. Associations between NIDU and HIV disease
progression and mortality [36,37], and current HAART use [42],
recently have been reported. However, our study provides
important new information from a large cohort on NIDU and
HAART use, both ever and over time. Given that persons with a
history of IDU and NIDU constitute a large proportion of HIV-
infected individuals, clarifying the effects of drug use on HAART
utilization in this subpopulation is important.
The current study showed that a history of IDU was associated
with a decreased likelihood of ever receiving HAART after
presentation for care. The lower likelihood of those with IDU
history remaining on HAART at JHU may reflect a higher
prevalence of active IDU in Baltimore compared to Nashville [43].
Certain factors related to ongoing IDU such as poor nutrition,
coexistent mental health disorders, hepatitis co-infection, and
weaker immune response, may limit the ability of persons with
IDU to tolerate or adhere to HAART [35,44].
For this analysis, NIDU history was assessed only in the CCC
cohort and was also associated with a lower likelihood of ever
receiving HAART as well as a decreased likelihood of remaining
on HAART $95% of the total follow-up time. NIDU affected
HAART utilization after adjusting for race, sex, follow-up time,
and baseline HIV-1 RNA and CD4
+ T cell count. To our
knowledge, this is the first analysis to assess NIDU and HAART
utilization in an HIV-infected population. The mechanisms by
which NIDU influences HAART utilization and exposure are
presumably similar to those for IDU [35], though the greater
heterogeneity of illicit substances included in our NIDU definition
make the magnitude of the observed association somewhat
surprising. Future studies should examine the specific influence
of individual NIDU substances and of polysubstance abuse,
categories that were not determined for this analysis.
An unexpected finding was that sex was associated with ever
receiving HAART as well as the probability of remaining on
HAART during the study period, but the direction of association
differed according to site of care. Females were more likely to
receive HAART at CCC, but were less likely to remain on
HAART when compared with men. At JHU, women were less
likely to receive any HAART, but once on therapy, sex was not
associated with likelihood of remaining on HAART. In a
Canadian cohort, women were significantly less likely to begin
HAART compared with men despite equal access to care [45],
and women were significantly less likely than men to be on
HAART in a US multi-center study [42]. Rates of HAART
discontinuation did not vary according to sex in a cohort from the
Southeastern US, but reasons for discontinuation did; women
were more likely to interrupt therapy due to non-adherence, to
report unique patterns of adverse events, and to spend more
cumulative time off HAART compared to men [46]. A recent
analysis of participants in the Women’s Interagency HIV Study
and the Multicenter AIDS Cohort Study found that older age and
Caucasian race were associated with a higher prevalence of
HAART-related symptoms, particularly among women; however,
depression and a prior diagnosis of AIDS were the strongest
predictors of symptoms in both cohorts [47]. Factors that influence
the decision to begin HAART may differ from those that affect the
ability to adhere to therapy. We speculate that the differential
associations observed in the present study are likely due to
unmeasured factors among females that differed between sites,
including cohort heterogeneity [48]. These might include activity
of substance use (especially IDU), pregnancy rates, co-morbidities
such as hepatitis C infection and mental health diagnoses, general
clinic practice patterns, and socioeconomic and housing statuses.
One of the strengths of this study, the ability to compare across
two geographically distinct urban cohorts, is also a potential
weakness. Differences in the clinic populations are evidenced by
IDU risk factor rates, baseline demographics such as age, race, and
sex, and time in follow-up. Among persons with an IDU risk
history, those in the JHU cohort were more likely to be female and
of black race than those in the CCC cohort, but the cohorts did
not differ significantly with respect to baseline HIV-1 RNA or
overall rates of HAART receipt. There also were differences in
ascertainment of drug use at CCC compared with JHU. Persons
classified solely on the basis of IDU history in both cohorts may
have injected heroin or stimulants, such as cocaine and
methamphetamine, and may also have used drugs through other
routes. Non-injection drug use was characterized only for the
CCC, and in this cohort half of those persons categorized with
historical IDU had active NIDU during the study period.
However, specific categories of NIDU were not distinguished in
the CCC analysis. Stimulant users are reported to have the
greatest risk of poor adherence compared with both non-drug-
users and non-stimulant drug users [11].
Methodological differences in data collection and different
ascertainment of behavioral information between CCC and JHU
may also have affected our findings. Medical chart review and data
abstraction were performed for CCC patients, whereas history of
IDU was determined for JHU patients on the basis of reported risk
factor for HIV acquisition. Documentation of substance use during
routine patient care could be affected by provider reliability or
individual presumptions. Also, substance-using individuals may
minimize the frequency and quantity of drug use depending on the
circumstances of self-report (e.g. personal interview versus anony-
mous survey), which were not standardized for either cohort.
Bias is inherent in observational data of this nature, and baseline
status may have differed among subjects. For example, not all
patients were HAART-naı ¨ve, some were on HAART, and others
may have initiated therapy later in the study period. Analyses
limited to persons whose baseline CD4
+ T cell count was #200
were performed in the CCC cohort to minimize these biases, as all
such persons would meet eligibility for HAART initiation. IDU
history remained strongly associated with decreased likelihood of
receipt of HAART in this model. Adherence to HAART was not
assessed for either cohort in this retrospective analysis. Although
we determined cumulative HAART exposure, we could not
account for unrecorded drug ‘‘holidays’’ or unreported treatment
interruptions that were relatively common in practice at times
during the study period [49].
Substance abuse is by nature a dynamic and chronic process,
and this variability may explain discordant findings in other studies
[32,38,50–52]. In a prior report of IDU in Baltimore, only
approximately 30% of individuals persistently used drugs during
an average follow-up of 8 years [53]. Switching from substance use
to non-use is strongly associated with improvements in antiretro-
viral therapy adherence and HIV treatment outcomes compared
with ongoing use [14,38,54]. Additionally, active substance users
experience extraordinary instability and are frequently transition-
ing residences, living on the street, or facing cyclic incarceration,
which may lead to nonpersistence with HIV therapy [16,55].
The present study demonstrated that for the CCC cohort,
associations between drug use, receipt of HAART, and propor-
tional time on HAART were not altered significantly whether
patients were categorized according to historical drug use or drug
Drug Use and HAART
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during or after HAART use. This contrasts with findings from
previous studies. For example, a prospective observational study
found that historic IDU or any illicit drug history were not
associated with decreased patient adherence to HAART, whereas
recent drug activity was associated with poorer adherence [10].
The association of decreased receipt of HAART in both persons
with historic drug use and active drug users may reflect patient-
related factors or, alternatively, characteristics of care providers
and the systems within which they work. After controlling for
numerous other covariates, Ding et al. found that persons with
IDU who were treated by physicians with negative attitudes
towards IDU were half as likely to have been exposed to HAART
compared to persons with non-IDU, or those treated by physicians
with positive attitudes [56]. In a multisite cohort of active injection
drug users, HAART use was independently predicted by better
patient-provider engagement and stable housing [57].
HIV infection and substance abuse are highly interrelated
chronic diseases with consequences that are expanding worldwide.
This study demonstrates important negative associations between
IDU, NIDU and HAART utilization. Future studies should better
characterize patient-level, provider-level, and structural factors
that may contribute to utilization of HAART in drug users, and
further clarify the effects of different types of drug use on HAART
utilization and HIV disease progression.
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